Beijing Tiantan Biological Products Co., Ltd.

SHSE:600161 Stock Report

Market Cap: CN¥37.7b

Beijing Tiantan Biological Products Balance Sheet Health

Financial Health criteria checks 6/6

Beijing Tiantan Biological Products has a total shareholder equity of CN¥13.8B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥15.6B and CN¥1.7B respectively. Beijing Tiantan Biological Products's EBIT is CN¥2.0B making its interest coverage ratio -22. It has cash and short-term investments of CN¥4.8B.

Key information

0%

Debt to equity ratio

CN¥0

Debt

Interest coverage ratio-22x
CashCN¥4.80b
EquityCN¥13.85b
Total liabilitiesCN¥1.71b
Total assetsCN¥15.55b

Recent financial health updates

We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Mar 16
We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Recent updates

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Low P/E No Reason For Excitement

Dec 23
Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Low P/E No Reason For Excitement

Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Oct 29
Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Beijing Tiantan Biological Products (SHSE:600161) Ticks All The Boxes When It Comes To Earnings Growth

Oct 27
Beijing Tiantan Biological Products (SHSE:600161) Ticks All The Boxes When It Comes To Earnings Growth

Calculating The Fair Value Of Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161)

Oct 08
Calculating The Fair Value Of Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161)

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Shares May Have Run Too Fast Too Soon

Sep 19
Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Shares May Have Run Too Fast Too Soon

Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?

Jul 23
Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?

Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value

Jun 09
Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings

May 22
Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings

We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Mar 16
We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?

Mar 01
Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?

Financial Position Analysis

Short Term Liabilities: 600161's short term assets (CN¥8.5B) exceed its short term liabilities (CN¥1.6B).

Long Term Liabilities: 600161's short term assets (CN¥8.5B) exceed its long term liabilities (CN¥153.6M).

Debt to Equity History and Analysis

Debt Level: 600161 is debt free.

Reducing Debt: 600161 has no debt compared to 5 years ago when its debt to equity ratio was 8%.

Debt Coverage: 600161 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 600161 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 16:37
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Beijing Tiantan Biological Products Co., Ltd. is covered by 25 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Changming HeBOCI Research Ltd.
Yue GaoChangjiang Securities Co. LTD.
Pei ChengChina Galaxy Securities Co., Ltd.